Diagnosing Thyroid-Stimulating Hormone (TSH)-Secreting Pituitary Adenomas by Short-Term Somatostatin Analogue Test

2019 ◽  
Author(s):  
Rulai Han ◽  
Liyun Shen ◽  
Jie Zhang ◽  
Jing Xie ◽  
Wenqiang Fang ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Thyroid Stimulating Hormone ◽  
Somatostatin Analogue ◽  
Short Term ◽  
Stimulating Hormone

Elevations in Thyroid-Stimulating Hormone in Normal Subjects after Receiving Short-Term Lithium Carbonate

1988 ◽  
Vol 22 (3) ◽  
pp. 202-204 ◽  
Author(s):  
Merlin V. Nelson ◽  
Vickie Tutag-Lehr ◽  
R. Lee Evans
Keyword(s):  
Lithium Carbonate ◽  
Normal Subjects ◽  
Thyroid Stimulating Hormone ◽  
Short Term ◽  
The Mean ◽  
Early Rise ◽  
State Concentration ◽  
Male Subjects ◽  
Stimulating Hormone

Nine normal, healthy male subjects had significantly elevated thyroid-stimulating hormone (TSH) concentrations while receiving oral lithium carbonate for two weeks. The mean minimum lithium serum concentration was 0.765 mEq/L. The TSH concentrations after 15 days on lithium were significantly correlated to the TSH concentration at baseline. No correlation was found between mean minimum lithium steady-state concentration and TSH concentration after 15 days on lithium. Further research is necessary to determine if a high baseline TSH concentration or an early rise in TSH will predict those patients who will eventually develop hypothyroidism after long-term lithium therapy.

Thyroid-stimulating hormone pituitary adenomas

2008 ◽  
Vol 109 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Michelle J. Clarke ◽  
Dana Erickson ◽  
M. Regina Castro ◽  
John L. D. Atkinson
Keyword(s):  
Radiation Therapy ◽  
Pituitary Adenomas ◽  
Anterior Pituitary ◽  
Transsphenoidal Surgery ◽  
Hormone Replacement ◽  
Residual Tumor ◽  
Thyroid Stimulating Hormone ◽  
Team Approach ◽  
Pituitary Dysfunction ◽  
Stimulating Hormone

Object Thyroid-stimulating hormone (TSH)–secreting pituitary adenomas are rare, representing < 2% of all pituitary adenomas. Methods The authors conducted a retrospective analysis of patients with TSH-secreting or clinically silent TSH-immunostaining pituitary tumors among all pituitary adenomas followed at their institution between 1987 and 2003. Patient records, including clinical, imaging, and pathological and surgical characteristics were reviewed. Twenty-one patients (6 women and 15 men; mean age 46 years, range 26–73 years) were identified. Of these, 10 patients had a history of clinical hyperthyroidism, of whom 7 had undergone ablative thyroid procedures (thyroid surgery/131I ablation) prior to the diagnosis of pituitary adenoma. Ten patients had elevated TSH preoperatively. Seven patients presented with headache, and 8 presented with visual field defects. All patients underwent imaging, of which 19 were available for imaging review. Sixteen patients had macroadenomas. Results Of the 21 patients, 18 underwent transsphenoidal surgery at the authors' institution, 2 patients underwent transsphenoidal surgery at another facility, and 1 was treated medically. Patients with TSH-secreting tumors were defined as in remission after surgery if they had no residual adenoma on imaging and had biochemical evidence of hypo-or euthyroidism. Patients with TSH-immunostaining tumors were considered in remission if they had no residual tumor. Of these 18 patients, 9 (50%) were in remission following surgery. Seven patients had residual tumor; 2 of these patients underwent further transsphenoidal resection, 1 underwent a craniotomy, and 4 underwent postoperative radiation therapy (2 conventional radiation therapy, 1 Gamma Knife surgery, and 1 had both types of radiation treatment). Two patients had persistently elevated TSH levels despite the lack of evidence of residual tumor. On pathological analysis and immunostaining of the surgical specimen, 17 patients had samples that stained positively for TSH, 8 for α-subunit, 10 for growth hormone, 7 for prolactin, 2 for adrenocorticotrophic hormone, and 1 for follicle-stimulating hormone/luteinizing hormone. Eleven patients (61%) ultimately required thyroid hormone replacement therapy, and 5 (24%) required additional pituitary hormone replacement. Of these, 2 patients required treatment for new anterior pituitary dysfunction as a complication of surgery, and 2 patients with preoperative partial anterior pituitary dysfunction developed complete panhypopituitarism. One patient had transient diabetes insipidus. The remainder had no change in pituitary function from their preoperative state. Conclusions Thyroid-stimulating hormone–secreting pituitary lesions are often delayed in diagnosis, are frequently macroadenomas and plurihormonal in terms of their pathological characteristics, have a heterogeneous clinical picture, and are difficult to treat. An experienced team approach will optimize results in the management of these uncommon lesions.

Active and Silent Thyroid-Stimulating Hormone−Expressing Pituitary Adenomas: Presenting Symptoms, Treatment, Outcomes, and Recurrence

2014 ◽  
Vol 82 (6) ◽  
pp. 1224-1231 ◽  
Author(s):  
Matthew A. Kirkman ◽  
Zane Jaunmuktane ◽  
Sebastian Brandner ◽  
Akbar A. Khan ◽  
Michael Powell ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Pituitary Adenomas ◽  
Thyroid Stimulating Hormone ◽  
Presenting Symptoms ◽  
Stimulating Hormone

scholarly journals Changes in tight junctions of thyroid epithelium with changes in thyroid activity.

1975 ◽  
Vol 66 (3) ◽  
pp. 657-663 ◽  
Author(s):  
L W Tice ◽  
S H Wollman ◽  
R C Carter
Keyword(s):  
Tight Junction ◽  
Tight Junctions ◽  
Cell Types ◽  
Thyroid Stimulating Hormone ◽  
Thyroid Activity ◽  
Short Term ◽  
Rat Thyroid ◽  
Thyroid Epithelium ◽  
Stimulating Hormone

The morphology of the tight junction of rat thyroid epithelium was examined in freeze-fractured material fixed in glutaraldehyde and briefly glycerinated. In normal thyroids the overall appearance of this junctional specialization resembled that of other cell types in many respects. Short-term changes in thyroid activity and hypophysectomy for 3 wk did not obviously affect the appearance of tight junctions. Feeding of the goitrogen, thiouracil, which stimulates secretion of thyroid-stimulating hormone, resulted in the appearance of some very narrow and some very wide, tight junctions or sometimes junctions with both wide and narrow regions within the same cell.

Diagnosing Thyrotropin-Secreting Pituitary Adenomas by Short-Term Somatostatin Analogue Test

Thyroid ◽  
2020 ◽  
Vol 30 (9) ◽  
pp. 1236-1244
Author(s):  
Rulai Han ◽  
Liyun Shen ◽  
Jie Zhang ◽  
Jing Xie ◽  
Wenqiang Fang ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Somatostatin Analogue ◽  
Short Term

Perianesthetic Management of Patients With Thyroid-Stimulating Hormone–Secreting Pituitary Adenomas

2017 ◽  
Vol 29 (3) ◽  
pp. 341-346 ◽  
Author(s):  
Matthew W. Dyer ◽  
Amy Gnagey ◽  
Bryan T. Jones ◽  
Roger D. Pula ◽  
William L. Lanier ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone

Thyroid-stimulating hormone pituitary adenomas and hyperthyroidism

1986 ◽  
Vol 25 (4) ◽  
pp. 361-368 ◽  
Author(s):  
Francois Grisoli ◽  
Toussaint Leclercq ◽  
Jean-Pierre Winteler ◽  
Philippe Jaquet ◽  
Michel Guibout ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Thyroid Stimulating Hormone ◽  
Stimulating Hormone
Sign in / Sign up

Export Citation Format

Share Document